Lipid Nanoparticle mRNA Delivery for Viable HSC Gene Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for delivering genetic material to hematopoietic stem cells (HSCs) are inefficient and cause significant cell death, limiting their application in gene editing and therapy.
Innovation Solution
A method involving preincubation of a serum factor with an LNP composition containing mRNA, amine lipid, helper lipid, neutral lipid, and PEG lipid, followed by in vitro contact and culture of the stem cells, to deliver CRISPR/Cas system components, reducing cell death and enhancing gene editing efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing methods are used to deliver genetic material to HSCs, then gene editing can be performed, but cell death is significant and delivery efficiency is low
Solution Approach 1:
The patent uses lipid nanoparticles (LNPs) as intermediary carriers to deliver mRNA encoding CRISPR/Cas system components to HSCs. The LNP composition includes ionizable lipids, helper lipids, and PEGylated lipids that protect the mRNA and facilitate cellular uptake while reducing cytotoxicity compared to direct delivery methods. This intermediary approach resolves the contradiction by enabling efficient gene editing delivery while minimizing cell death through controlled encapsulation and targeted release.
Solution Approach 2:
The patent optimizes multiple parameters of the LNP system including lipid composition ratios, mRNA sequence design, particle size distribution, and delivery conditions to maximize transfection efficiency while minimizing cellular toxicity. By systematically adjusting these parameters, the method achieves high delivery efficiency to HSCs without causing significant cell death, directly resolving the technical contradiction between reliability and harmful effects.
2Productivity
If traditional transfection methods are used, then genetic material can be introduced, but the process is inefficient and causes cell death
Solution Approach 1:
The patent replaces mechanical transfection methods (such as electroporation or microinjection) with a biochemical delivery system using lipid nanoparticles. This substitution eliminates the mechanical stress and physical damage associated with traditional methods, thereby maintaining high gene editing efficiency while preserving cell viability. The LNP-mediated delivery achieves productive gene editing without the harmful mechanical effects of conventional approaches.
Solution Approach 2:
The patent employs composite lipid nanoparticle formulations combining multiple lipid types (ionizable lipids, helper lipids, PEGylated lipids) with mRNA cargo to create a delivery system that is both highly effective at gene editing and gentle to cells. This composite material approach enables high productivity in gene editing while maintaining cell viability, resolving the contradiction between editing efficiency and cell survival.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves efficient delivery of mRNA to HSCs with reduced cell death, enabling effective gene editing and production of genetically engineered cells.
Implementation Method 1
contacting the stem cell or the stem cell population with the preincubated LNP composition in vitro; thereby delivering the mRNA to the stem cell or the stem cell population
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
The present disclosure relates to compositions and methods for introducing an mRNA into stem cells, such asHSPCs, and for delivering gene editing components to such cells in vitro. For example, the disclosure relates to modifying a gene sequence using a CR1SPR-Cas9 complex in HSPCs, and methods and delivery systems for achieving such gene modification in HSPCs.